News

The passage of the FDA Safety and Innovation Act will support innovation, answer the current shortages, and even regulate mobile applications.

New molecular entity: FDA approved taliglucerase alfa (Elelyso, Pfizer), a recombinant active form of the glucocerebrosidase enzyme for long-term enzyme replacement therapy (ERT) for adults with type 1 Gaucher disease.

New formulation: FDA approved pancrelipase delayed-release capsules (Pertyze, Digestive Care, Inc.) for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other conditions.

The Institute of Medicine reports that a number of issues are causing a number of barriers to successful HIV care in the United States.

Atrial fibrillation(AF) is the most common sustained cardiac arrhythmia and a potent risk factor for stroke. Here's a review of new oral anticoagulants for stroke prevention with AF.

The introduction of the immunomodulatory drugs and bortezomib, a proteasome inhibitor, has dramatically improved outcomes in patients with relapsed or refractory multiple myeloma.

Screening for hepatitis-C may soon become a routine screening for Baby Boomers.

A new study seems to indicate that adding cetuximab to the standard therapy for resected stage 3 colon cancer provides no additional benefits.

Recent FDA action (through July 2012) related to, morphine and oxycodone Dual Opioid platform, MoxDuo, QRxPharma, apixaban, Eliquis, Bristol-Myers Squibb, RG1068, Repligen, Multi-Stem, Athersys, Rivaroxaban, Xarelto, Janssen, Ocriplasmin intravitreal injection, ThromboGenics, Regorafenib, Bayer, Onyx Pharmaceuticals, Pregabalin, Lyrica, Lupin, Diclofenac sodium and misoprostol, Arthrotec, Watson, Next Choice One Dose, Plan B One-Step

A recent study from JAMA indicates that most Americans aren't meeting the necessary goals to lower CV risks.

Recent FDA Approvals (through July 2012) related to (Vivus, Gilead Sciences, Orasure, Pfizer, Ferring Pharmaceuticals, Eli Lilly, Bristol-Myers Squibb, Qiagen, Astellas Pharma US, Roche Molecular Systems, Arena Pharmaceuticals, Eisai)

A review of drug therapies and research presented at the 2012 Scientific Session of the American Diabetes Association.

Social media is moving beyond the solely social sphere to influence engagement and outcomes.

A large health insurer in Hawaii is taking an aggressive step away from the traditional fee-for-service delivery system.

Employers looking for ways to reduce healthcare costs are finding consumer-driven health plans (CDHP) to be attractive choices as they wait for the health insurance exchanges to go live.

The GOP is looking to gain control of the White House and Congress to restructure healthcare.

PPACA's rate boost only goes so far

The pressure is on to reduce costs, and many plans are finding creative ways to outsource operation functions.

Medicaid 2.0 will hit state markets in the pocketbook.

Among the decisions employers are tackling is whether to keep their group health plans.

Four executives discuss HIV/AIDS, treatment options, and how things have changed in 30 years

Insurers move toward a consumer-facing, retail marketplace.

Despite front-end scrutiny, payers seek audit process to improve high-cost specialty pharmacies.

Health reform provisions must be deemed lawful by the Administrative Procedure Act.

A white paper from Thomson Reuters indicates that organized crime is entering the healthcare fraud market.

Much to the delight of providers, insurers have reduced claims-processing errors by a substantial amount thanks to streamlined adjudication.

Slow-release depot antipsychotics help manage schizophrenia.

FDA has approved carfilzomib (Kyprolis, Onyx Pharmaceuticals) to treat patients with multiple myeloma who have received at least 2 prior therapies, including treatment with bortezomib (Velcade, Takeda) and an immunomodulatory therapy.